Photo from wikipedia
The clinical outcomes of ABO‐incompatible (ABOi) kidney transplantation have improved with the introduction of desensitization therapy with rituximab. However, rituximab prevents not only antibody‐mediated rejection (AMR) but also increases the… Click to show full abstract
The clinical outcomes of ABO‐incompatible (ABOi) kidney transplantation have improved with the introduction of desensitization therapy with rituximab. However, rituximab prevents not only antibody‐mediated rejection (AMR) but also increases the risk of adverse events, such as infection. For ABOi kidney transplantation in patients with low anti‐A/B antibody titers, we previously used a rituximab‐free desensitization protocol and then initiated a single dose of 100 mg rituximab in 2016. We retrospectively compared the outcomes of ABOi kidney transplantation in patients with low anti‐A/B antibody titers before and after the introduction of rituximab.
Journal Title: Clinical Transplantation
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!